DrugComb: an integrative cancer drug combination data portal

Area of Science:

• Computational biology
• Pharmacology
• Bioinformatics

Background:

• Drug combination therapy offers potential benefits like enhanced efficacy and reduced toxicity.
• Identifying synergistic drug combinations is traditionally difficult and time-consuming.
• High-throughput screening advances accelerate discovery, but require robust informatics support.

Purpose of the Study:

• To create an open-access data portal, DrugComb, for managing and analyzing drug combination screening data.
• To provide tools for users to analyze their own data and contribute to a crowdsourced database.
• To facilitate efficient data utilization for future drug combination discovery.

Main Methods:

• Development of the DrugComb open-access data portal (https://drugcomb.fimm.fi).
• Collection and harmonization of 437,932 drug combinations tested on cancer cell lines.
• Application of linear regression models using chemical fingerprints to predict drug combination sensitivity.

Main Results:

• The DrugComb portal provides a centralized repository for drug combination screening data.
• Users can analyze and visualize their own data, and contribute to the growing database.
• Linear regression models demonstrated high accuracy in predicting drug combination sensitivity.

Conclusions:

• The DrugComb portal and associated tools streamline drug combination discovery.
• Accessible data and informatics approaches are crucial for advancing combination therapy research.
• This resource accelerates the identification of effective drug combinations for cancer treatment.